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Proprotein processing is essential for HIV infectivity. Cellular trans-Golgi network (TGN) serine proteases (e.g., furin) are required to
cleave HIV envelope gp160 to gp120. In addition, HIV protease (PR), an aspartyl protease, cleaves p55Gag to p24, etc., in budding virions.
a1-Antitrypsin (a1AT) is cleaved by serine proteases, causing a conformational change in a1AT that sequesters and so inactivates the
protease. a1AT blocks both gp160 and p55 processing, and so is a powerful inhibitor of HIV replication. We hypothesized that a1AT
inhibited gp160 and p55 processing via different mechanisms, and that in both cases, a1AT bound and was itself cleaved by the proteases
whose activities were blocked. a1AT delivered by SV(AT), a recombinant, Tag-deleted SV40-derived vector, localized to the TGN, co-
precipitated with furin, and depleted furin from the TGN. After SV(AT) transduction and HIV challenge, a1AT was detected in resulting
nascent immature HIV-1 virions. a1AT also blocked incorporation of the enzymatically active dimeric form of PR into HIV virions. Western
analysis using recombinant proteins showed that a1AT directly bound HIV PR, and was cleaved by it. The simultaneous inhibition of two
different steps in HIV morphogenesis both increases a1AT antilentiviral activity and decreases the possibility that HIV mutations will allow
escape from inhibition.D 2003 Elsevier B.V. All rights reserved.Keywords: Serpin; SV40; Furin; HIV-1 protease; gp160; p55Gag1. Introduction
Viral proprotein processing is a ubiquitous process that is
often necessary to produce infectious virions. The HIV viral
envelope proprotein, gp160, must undergo proteolytic
cleavage to liberate its active constituents, gp120 and
gp41 [1,2]. Gp120 mediates the initial interaction with
cellular CD4 receptor and HIV co-receptors, while gp41
both anchors gp120 to the virus envelope and is needed for
virus entry into the cell [3,4]. Gp160 is cleaved at a highly
conserved pair of basic amino acids. Evidence accumulated
over the last decade indicates that this event involves a
family of cellular calcium-dependent serine proteases, called
substilisin-like protein convertases (SPCs). Among the
seven known members of this family, furin was the first
that was shown to cleave gp160 intracellularly into gp120/
gp41 [5]. Furin is ubiquitously expressed at low levels, and0925-4439/03/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
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work/endosomal system (TGN). The wide variety of furin-
cleaved proproteins highlights the crucial role of this en-
zyme in numerous cellular and pathological events.
In addition to processing of its envelope, HIV requires
processing of Gag and Gag–Pol polyproteins. Unlike Env
processing, these reactions are performed by HIV-1 protease
(PR), an aspartyl protease. PR cuts its substrates at specific
sites, to release several proteins that are required for HIV
viral particles to assemble, and for the infectivity of daugh-
ter virions. Just as cellular serine protease activity is
obligatory for envelope maturation, this viral aspartyl pro-
tease activity is necessary for Gag proprotein processing.
Both proteolytic processes are necessary to generate infec-
tious viral progeny.
a1-Antitrypsin (a1AT) is a serine protease inhibitor (ser-
pin), with principal specificity for neutrophil elastase. a1AT
exerts its inhibitory activity by acting as a substrate for
certain serine proteases, then binding and sequestering them,
once they excise a small fragment of the a1AT C-terminus.
We recently reported that delivering wild-type human a1AT
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phocyte cultures using a recombinant SV40 vector
(SV(AT)) strongly inhibited replication and spread of HIV-
1. This inhibition was especially potent because a1AT
blocked two necessary components of HIV-1 proprotein
processing: cellular serine proteases that cleave gp160 to
gp120 + gp41; and, surprisingly, HIV-1 PR, an aspartyl
protease that cleaves p55Gag within budding HIV viral
particles [6]. Here, we report on the mechanisms underlying
those observations. Thus, native a1AT delivered to T cells
by SV(AT) inhibited HIV-1 gp160 processing, at least in
part, by blocking cellular furin in SV(AT)-transduced cells.
We also show that a1AT directly associated with, was
cleaved by, and inhibited, HIV-1 PR, an aspartyl protease
both in tube and in vitro. a1AT is thus a previously
undescribed substrate for, and inhibitor of, HIV-1 PR.2. Materials and methods
2.1. Cell culture
The COS-7 cell line that is used to package rSV40
vectors was maintained in Dulbecco’s modified Eagle’s
medium (DMEM) as described previously [5]. The same
culture conditions were used for HeLa cells. SupT1 cells, a
human T lymphocyte cell line permissive to HIV-1 infec-
tion, was grown in RPMI-1640 medium as described before
[7]. All the cells were grown at 37 jC in humidified
incubator with 5% CO2.
2.2. Plasmids and viral expression constructs
The molecular clone of HIV-1 used in these studies was
pNL4–3. This strain was obtained from the NIH AIDS
Reference Reagent Repository Program, and was passaged
and titered as described previously. HIV-1NL4–3 is a highly
cytopathic T-tropic viral strain.
Construction of recombinant SV40 derivative viruses
(rSV40) for gene transfer has been described previously
[8,9]. The construct pT7ma1AT, which encodes human
a1AT cDNA has been described previously, as has SV(AT),
the rSV40 vector derived from it [10]. The control virus for
these studies, SV(HBS), carries the cDNA for hepatitis B
surface antigen (HBsAg) [11].
2.3. Production of rSV40 derivative virus
The techniques used to generate rSV40 virus from such
plasmids as pT7ma1AT have been described [9]. Essential-
ly, a1AT in this plasmid is the native, wild-type human
protein, driven by two tandem SV40 promoters. SV(AT),
the derivative virus, and all other rSV40 vectors described,
are replication-incompetent. Virus stocks were prepared as
cell lysates then purified as described elsewhere [9], and
were titered by in situ PCR [8].2.4. Transduction
For transduction with SV40-derived viruses, SupT1 and
HeLa cells were treated for 24 h at a multiplicity of infection
(MOI) of 10. This treatment was repeated twice on sequen-
tial days at a MOI of 3. No selection was used. The rSV40-
treated cells were then cultured for 5 days before further
manipulation.
2.5. HIV-1 protease assay
HIV-1 protease assay protocol was adapted from [12,13].
Briefly, purified HIV-1 PR (500 ng, NIH-ARRRP), recom-
binant human a1AT (1–5 Ag, Sigma) and purified p55Gag
(500 ng, NIH-ARRRP) were combined in 2 mM EDTA, 1
M NaCl, 0.2 M Na2PO4 and 20% glycerol, pH 7.1 on ice.
High salt was included in the assay because it gave more
consistent enzyme activity. HIV-1 PR activity was initiated
by lowering pH to 5.5 using 0.4 M acetic acid. Enzymatic
reactions were carried out at 37 jC and stopped by addition
of SDS-containing 2 sample loading buffer. Samples
were reduced by boiling in beta-mercaptoethanol. Proteins
were separated by 4–20% Ready SDS-PAGE (Bio-Rad) and
transferred to a PVDF-Plus membrane (Osmonics, Minne-
tonka, MN). To study a1AT cleavage, proteins were loaded
on 15% SDS-PAGE.
2.6. Immunoprecipitation and Western analysis
For in vitro studies, cells were pelleted by centrifugation
for 5 min at 1500 rpm, washed twice with PBS buffer, and
resuspended in 1 ml of lysis buffer (50 mM Tris, pH 7.4/150
mM NaCl/1% Nonidet P-40/1% Sodium deoxycholate/1
protease inhibitor mix (Sigma)/0.5 mM sodium orthovana-
date/0.02% sodium azide) and digested 15 min at 4 jC.
Cleared supernatants were used as cell lysates. Cell lysates
(500 Ag) were subjected to immunoprecipitation overnight
at 4 jC with goat anti-antitrypsin antibody (Sigma), or
rabbit anti-furin antibody (ABR). For HIV-1 PR precipita-
tion using a1AT antibodies from HIV-1 virions, 100 Ag of
viral proteins were used. Protein A-Sepharose (Pharmacia)
was added (50 Al of 50% slurry) to the immunoprecipitation
reactions and incubated for 2 h at 4 jC. Sepharose beads
were extensively washed and resuspended in SDS sample
loading buffer.
Proteins were separated by 4–20% Ready SDS-PAGE
(Bio-Rad) and transferred to a PVDF-Plus membrane
(Osmonics). After room temperature blocking for 4 h (PBS
(pH 7.4)/0.1% Tween-20 + 5% dry milk), blots were incu-
bated overnight at 4 jC with either polyclonal ABR
(1:1000) or polyclonal anti-HIV-1 PR antibody (NIH-
ARRRP, 1:500). Secondary horseradish peroxidase-conju-
gated goat anti-rabbit or sheep anti-goat antibodies (Pierce)
diluted 1:10,000 in PBS (pH 7.4)/0.1% Tween-20 were
added, and blots were incubated for 1 h at room tempera-
ture. Each antibody incubation was followed by extensive
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performed as directed by the manufacturer.
2.7. Protein sequencing
To minimize thermal band distortion, proteins were
separated by 4–20% Ready SDS-PAGE (Bio-Rad) at 90
V for 1 h at room temperature. Proteins were then trans-
ferred on ProBlott filter (Applied Biosystems) at 50 V (170
mA) for 30 min at room temperature in electroblotting
buffer (1 CAPS in 10% methanol).
Protein samples on ProBlott were detected using con-
ventional Coomassie brilliant blue staining. Briefly, Pro-
Blott filters were saturated with 100% methanol for a few
seconds, then stained for 15 min using Coomassie brilliant
blue following the manufacturer’s recommendations. After
extended destaining in 50% methanol, membrane was
thoroughly rinsed with deionized water. The bands of
interest were excised with a razor blade. ProBlott discs
were then desalted, digested and N-terminal sequencing was
conducted using Applied Biosystems Protein Sequencers at
the Kimmel Cancer Center Protein Facility (Thomas Jeffer-
son University, Philadelphia, PA). Sequencing products
were identified using GenBank database.
2.8. Immunocytochemical analysis
Localization of a1AT in SV(AT)-transduced SupT1 and
HeLa cells was determined by indirect immunofluorescence
as previously described [6]. Briefly, cells were fixed for 20
min at room temperature (RT) in PBS pH 7.4 containing 4%
formaldehyde. After extensive washing in PBS, cells were
permeabilized using 0.1% NP40 in PBS for 10 min at RT.
Cells were extensively washed in PBS. Non-specific stain-
ing was blocked using normal donkey serum, overnight at 4
jC. Incubation with primary and secondary antibodies was
done at 37 jC for 1 h. The goat anti-human a1AT antibody
(Sigma) was used at a dilution of 1:200 in PBS. Rabbit anti-
giantin antibody (Covance) was used at a dilution of 1:500,
and the rabbit ABR was used a dilution of 1:200, both in
PBS. When primary antibody was from goat, the immuno-
reaction was detected using an Alexa Fluor 586-conjugated
secondary antibody raised in donkey (Molecular Probes)
diluted 1:1000 in PBS. When primary antibodies were from
rabbit, the immunoreaction was visualized using an Alexa
Fluor 548-conjugated secondary antibody raised in donkey
(Molecular Probes) diluted 1:1000 in PBS. Slides were
washed extensively and mounted using Vacushield mount-
ing medium, then analyzed using an epifluorescence micro-
scope (Olympus) or confocal microscope (Bio-Rad
MR600).
2.9. Preparation of HIV-1 virions
SupT1 cells (1.0 106) were exposed overnight to HIV-
1NL4–3 as indicated in the figure legends. The next day, cellswere washed with prewarmed, serum-free medium to re-
move input virions and maintained in complete medium.
Cell-free culture supernatants (5 ml) were harvested at day 5
post-infection, and ultracentrifuged at 35,000 g for 180
min at 4 jC. Virus pellets were resuspended and lysed on ice
in 1 ml of lysis buffer (50 mM Tris, pH 7.4/150 mM NaCl/
1% Nonidet P-40/1% Sodium deoxycholate/1 protease
inhibitor mix (Sigma)/0.5 mM sodium orthovanadate/0.02%
sodium azide) for 15 min before further analysis.
2.10. Preparation of crude subcellular fractions
SupT1 cells (1.0 106) mock-transduced or expressing
a1AT or HBsAg proteins were washed twice in PBS pH 7.4
then disrupted using a Dounce homogenizer (50 strokes) in
0.25 M sucrose, 1 mM EDTA, 10 mM HEPES-NaOH, pH
7.4. The nuclear fraction was pelleted by centrifugation at
1000 g for 10 min at 4 jC. The heavy mitochondrial
fraction was recovered after centrifugation at 3000 g for
10 min at 4 jC of the post-nuclear supernatant. The light
microsomal fraction containing Golgi membranes, vesicles
from the TGN and endoplasmic reticulum was pelleted by
centrifugation of the heavy mitochondrial supernatant at
17,000 g for 10 min at 4 jC. Pellets were lysed on ice in
lysis buffer (50 mM Tris, pH 7.4/150 mM NaCl/1% Nonidet
P-40/1% Sodium deoxycholate/1 protease inhibitor mix
(Sigma)/0.5 mM sodium orthovanadate/0.02% sodium
azide) for 15 min before further analysis.3. Results
3.1. a1AT associates with furin and decreases immunode-
tectable furin in the TGN
3.1.1. a1AT colocalizes with furin in the TGN
HIV-1 gp160 Env proprotein is processed in the TGN to
gp120 and gp41. This catalytic cleavage of gp160 is
generally considered to be done by one or more cellular
serine proteases of the substilisin family. Because furin is
most frequently held responsible for gp160 processing, we
first examined the subcellular localization of a1AT delivered
by transduction with SV(AT). Thus, HeLa cells were trans-
duced with SV(AT) as described in Materials and methods.
Such treatment routinely transduces >95% of these cells,
without selection [6]. Confocal immunocytochemical anal-
ysis of a1AT delivered by SV(AT) 3 days earlier to HeLa
cells demonstrated it to be primarily localized in the
perinuclear zone resembling the TGN (Fig. 1A). Control
HeLa cells transduced with SV(HBS), did not express a1AT.
To better localize SV(AT)-delivered a1AT, we used the
TGN marker giantin (Fig. 1A). We observed a high degree
of overlap in the subcellular distribution of these two
proteins, as shown by the predominance of yellow.
We next compared the localization of a1AT and furin in
HeLa cells 4 days after SV(AT) treatment. The cellular
Fig. 1. SV(AT)-delivered a1AT localized to the TGN with furin. (A) HeLa cells were transduced with SV(AT) or SV(HBS) for 4 days, then examined by
confocal microscopy after being co-immunostained for a1AT (upper) and giantin (middle). The merged confocal immunofluorescence micrograph is shown in
the lower frames. (B) HeLa cells were transduced with SV(AT) for 4 days, then co-immunostained for a1AT and furin.
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Fig. 2. SV(AT)-delivered a1AT associates with, and depletes immunor-
eactive cellular furin. (A) SupT1 cells were transduced with SV(AT) for 7
days. Equal amounts of cellular protein from SV(AT) or SV(HBS)-
transduced SupT1 cells were subjected to immunoprecipitation using
specific antibodies against a1AT. Co-precipitated proteins were analyzed by
Western blot using an anti-furin probe. Positions of enzyme (E) and
enzyme– inhibitor complex (EI) are indicated. (B) SupT1 cells were
transduced with SV(AT) or SV(HBS) for 1 week before fixation and
staining for furin. Results are representative of three immunostainings
performed on three separate transductions. (C) SupT1 cells were transduced
with SV(AT), SV(HBS) or mock-transduced for 2 weeks. Subcellular
structures were fractionated by ultracentrifugation. Proteins from the light
mitochondrial fraction (containing TGN) were analyzed by Western
blotting using anti-furin and anti-giantin antibodies.
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(Fig. 1B, red) were similar. Superimposition of the two
images revealed that these proteins colocalized (Fig. 1B,
yellow) to paranuclear structures consistent with the Golgi
apparatus. These studies suggested that a1AT, furin and
giantin were situated virtually identically. In addition to this
paranuclear TGN disposition, a1AT was also found in a
punctate distribution in the cytoplasm.
3.1.2. Formation of furin–AT complexes
A hallmark of the serpin–serine proteinase interaction is
the formation of a complex that is stable to heating and even
to SDS [14]. Direct interaction of furin and a1AT was
confirmed by co-immunoprecipitation of both enzymes
from cell protein preparations of SV(AT)-transduced SupT1
cells, 3 days post-transduction (Fig. 2A). a1AT formed the
characteristic SDS-stable complex (EI) with furin (E) in
SV(AT)-transduced SupT1 cells. This complex migrated
with apparent molecular mass of f 200 kDa. No furin
could be detected in anti-a1AT immunoprecipitates from
control (SV(HBS))-transduced SupT1 cells.
3.1.3. Selective cellular depletion of furin by a1AT
The ability of SV(AT)-delivered a1AT to block process-
ing of gp160 suggested that this serpin inhibited TGN serine
protease activity. Although the specific cellular serine pro-
tease(s) responsible for gp160 cleavage is(are) not defini-
tively identified, furin is a prototypical TGN serine protease
that has been suggested as being involved in HIV Env
processing. Because a1AT binds and sequesters target
proteases, we examined the effect of SV(AT) transduction
on free cellular furin. By 1 week post-transduction with
SV(AT), a1AT greatly reduced the level of detectable
endogenous furin in SupT1 cells, as assessed by immunos-
taining (Fig. 2B). We therefore fractionated the subcellular
compartments of SV(AT)-transduced cells and control cells
by differential centrifugation as described in Materials and
methods. The light mitochondrial fraction in this fraction-
ation procedure is enriched in TGN structures [15]. Western
blot analysis of light mitochondrial fraction proteins further
indicated that by 2 weeks after SV(AT) transduction, a1AT
depleted cellular production of immunologically detectable
furin, but had no effect on the control TGN protein, giantin
(Fig. 2C). Together with the likely involvement of furin in
activating HIV-1 Env, our findings strongly suggested that
in SV(AT)-transduced cells, the observed a1AT inhibition of
gp160 processing [6] paralleled a1AT depletion of cellular
furin.
3.2. a1AT colocalizes with, binds to, and inhibits HIV-1 PR
The ability of a1AT to inhibit HIV-1 PR [6] was both
surprising and perplexing. The possible interaction of a1AT
with HIV-1 PR was analyzed by immunostaining. Thus,
HIV susceptible SupT1 cells were transduced as described
in Materials and methods with SV(AT), then challenged
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then analyzed by immunostaining for SV(AT)-delivered
a1AT and HIV-1 PR. HIV-1 PR confocal immunostaining
was observed in a punctate distribution (Fig. 3A1). In
contrast to SV(AT)-transduced cells that were not infected
with HIV, a1AT distribution in SV(AT) transduced cells that
were challenged with HIV-1 was not restricted to the TGN
(Fig. 3A2 and A3). Rather, in addition to the TGN locali-
zation of a1AT in unchallenged cells, a1AT was also
distributed in a punctate pattern similar to that seen for
HIV-1 PR. PR immunostaining was comparable in HIV-
infected cells, whether or not they had been transduced with
SV(AT) (Fig. 3B) or control rSV40s (data not shown). InFig. 3. Cellular localization of SV(AT)-delivered a1AT in HIV-infected cells. (A) S
with 0.1 MOI of HIV-1 (1, 3, 4) or not (2). Eight days later, cells were co-immunos
and giantin (GIANTIN, 4) (lower panel). (B) HIV-1 PR expression in SV(AT)-tra
SV(HBS), cultured for 2 weeks, then challenged with 0.1 MOI of HIV. Eight dacontrast, immunodetectable furin was obviously diminished
in cells treated with SV(AT). These data suggested that
a1AT inhibition of PR activity might not occur within the
cytosol but rather that a1AT might be incorporated into
developing HIV-1 virions, while its binding to PR may
explain the inhibition of HIV-1 PR previously observed in
HIV virions made by SV(AT)-transduced cells [6].
We tested this possibility by looking for a1AT-PR
association using concentrated preparation of HIV-1 virions
preparations from SV(AT)-transduced, HIV-infected cells.
Unselected and uncloned SV(AT)-transduced and SV(HBS)-
transduced SupT1 cells were treated with 0.1 MOI of HIV-
1NL4–3. Cell-free culture supernatants were harvested 5 daysupT1 cells were transduced with SV(AT) for 2 weeks, and then challenged
tained for HIV-1 PR (PR, 1) and a1AT(AT, 2) (upper panel), or a1AT(AT, 3)
nsduced, HIV-infected cells. SupT1 cells were transduced with SV(AT) or
ys later, cells were immunostained for HIV PR.
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(see Materials and methods). These virion preparations
were analyzed by Western blotting for a1AT, PR and
a1AT–PR complexes. We found that PR in its active
(dimeric) form was only seen in progeny virions from
SV(HBS)-transduced cells (Fig. 4A). On the other hand,
inactive (monomeric) PR co-precipitated with a1AT in HIV-
1 virions recovered from HIV-1-challenged, SV(AT)-trans-
duced SupT1 cells (Fig. 4B).
Since HIV-1 PR binds p55Gag and cleaves it into its
various active substituent peptides, we asked whether com-Fig. 4. a1AT is incorporated into budding virions and binds to HIV PR. (A) Sup
challenged with 0.1 MOI of HIV-1. Proteins from HIV virions progeny were anal
transduced with SV(AT) or SV(HBS) for 2 weeks, and then challenged with 0.1 M
(B) SupT1 cells were immunoprecipitated with an anti-a1AT antibody. Co-prec
antibody or (C) anti-p24 Gag. (D) SupT1 cells were transduced with SV(AT) or S
from HIV virions progeny were analyzed by Western blotting using an anti-a1ATplexes between these three proteins-a1AT, PR and p55Gag-
could be detected. We found that a f 40 kDa intermediate
of p55Gag proprotein immunoprecipitated with a1AT (Fig.
4C). Finally, a1AT was easily detected by Western blotting
in virions from SV(AT)-transduced cells (Fig. 4D). Taken
together, these results suggested that a1AT binds to HIV-1
PR, to p55Gag, and is incorporated into nascent immature
HIV-1 virions.
Interactions between a1AT and HIV-1 PR were further
studied in tube, using recombinant proteins. After incuba-
tion of recombinant a1AT and purified HIV-1 PR for 5 to 60T1 cells were transduced with SV(AT) or SV(HBS) for 2 weeks, and then
yzed by Western blotting using an anti-HIV PR antibody. SupT1 cells were
OI of HIV-1. Progeny virions from SV(AT)-transduced, HIV-1-challenged
ipitated proteins were analyzed by Western blotting with an anti-HIV PR
V(HBS) for 2 weeks, and then challenged with 0.1 MOI of HIV-1. Proteins
antibody.
Fig. 6. a1AT inhibits HIV PR activity. (A) Recombinant a1AT, HIV PR and
p55 were added to each other in tube. After 30 min, proteins were analyzed
by Western blotting using anti p24 antibody as a probe as described in
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blotting (Fig. 5). Co-incubation of PR and a1AT gave a
band at Mrf 60 kDa, which is consistent with a1AT (54
kDa) complexed with monomeric PR (10 kDa).
Our previous findings [6] that HIV virions made from
SupT1 cells expressing a1AT showed little p24
Gag was
consistent with possible a1AT inhibition of HIV-1 PR
cleavage of p55Gag. This possibility was further examined
using recombinant proteins. Various combinations of a1AT,
HIV-1 p55Gag and purified HIV-1 PR were incubated for 1
h at 37 jC (see Materials and methods). Reaction mixtures
were analyzed by Western blot using anti-p24 antibodies
(Fig. 6A). When recombinant HIV-1 PR was added to
p55Gag, no residual p55 was seen indicating that HIV-1
p24Gag was fully cleaved from its precursor. However, when
a1AT was added to the mixture, HIV-1 PR no longer fully
processed p55Gag: p24Gag formation was greatly reduced,
and a major cleavage product of f 40 kDa was seen.
Amino-terminal sequencing of this peptide demonstrated
that it was the result of excision of p17Gag by HIV-1 PR.
The f 40 kDa p55Gag cleavage intermediate produced with
co-incubation of PR in the presence of a1AT was thus
consistent with incompletely processed p24 + p6 + p9 poly-
protein.
HIV-1 PR is enzymatically active only as a homodimer.
This dimeric form of PR has a single active site, composed
of residues from the two identical monomers. Western
blotting of purified HIV-1 virions made by SV(AT)-trans-
duced cells was done as described before. Virions pro-
duced in the absence of SV(AT) transduction showed a
strong 20-kDa PR band (Fig. 6B). However, the mono-
meric (inactive) form of HIV-1 PR was the predominant
species detected in HIV-1 virion preparations recovered
from SV(AT)-transduced SupT1 cells, confirming results
obtained in Fig. 4A.Fig. 5. a1AT directly binds to HIV-1 PR. Purified a1AT and HIV PR were
mixed for the times indicated then analyzed by Western blot using anti-HIV
PR antibody as described in Materials and methods.
Materials and methods. (B) SupT1 cells were transduced with SV(AT) or
SV(HBS) for 2 weeks, and then challenged with 0.1 MOI of HIV-1. Eight
days later, progeny virions from SV(AT)-transduced, HIV-1-challenged
SupT1 cells were analyzed by Western blot using anti-HIV PR antibody as
described in Materials and methods.a1AT inhibition of (e.g.) neutrophil elastase involves the
cleavage of a1AT by that serine protease, with subsequent
immobilization of the protease within a pocket in a1AT
[16–18]. That is, often a1AT is cleaved by its target
protease and the cleaved form of a1AT immobilizes the
protease and prevents its subsequent interaction with other
substrates [19,20]. We tested whether a1AT also acted as a
substrate for HIV-1 PR. Purified a1AT and PR were incu-
bated together. The protein mixture was then electrophor-
esed. Coomassie blue staining showed a molecular species
of f 51.5 kDa, consistent with cleavage of a1AT by HIV-1
PR (Fig. 7). N-terminal sequencing revealed that HIV-1 PR
had cleaved a1AT at amino acid #25, (PVSLA#EDPQG).
These residues are in an exposed a-helix of a1AT, and
resemble p24–p1 cleavage site (ARVL#AEAM) of HIV-1
Fig. 7. a1AT is a substrate for HIV PR. Purified a1AT and HIV PR were
mixed for 30 min at 37 jC. Then analyzed by Coomassie blue staining as
described in Materials and methods.
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activation. Thus, the rate of complex formation, cleavage of
a1AT and loss of PR enzymatic activity are coupled. Taken
together, these results strongly suggest that a1AT binds to
and directly inhibits dimeric HIV-1 PR, an aspartyl protease.
Furthermore, a1AT is described for the first time as a
substrate for HIV-1 PR.4. Discussion
The ability of HIV to mutate and thus circumvent
therapeutic approaches designed to inhibit its many func-
tions has frustrated attempts to contain the AIDS epidemic
and to improve the lives of affected individuals. Against this
background, an approach to inhibiting HIV-1 that exploits
the virus’ need for less readily mutated cellular functions is
of considerable interest.
Host-dependent HIV-1 proprotein processing by cellular
enzymes represents a key element in the HIV replicative
cycle. Cleavage of HIV-1 Env gp160 requires one or more
cellular serine proteases of the substilisin family. It is not yet
clear which or how many of these enzymes catalyses gp160
conversion into gp120 and gp41 in lymphocytes and mono-
cytes. We have recently reported that delivering a1AT to
human lymphocytic cell lines or primary human lympho-
cytes using SV(AT) as a vector strongly inhibits HIV-1
replication and spread [6]. The likely mechanism for this
effect is in part direct inhibition of cellular serine proteases
that process gp160. HIV-1 Env processing occurs in the
TGN, by resident cellular serine proteases. We asked
whether a1AT expressed by SV(AT)-transduced cells local-
ized within cellular secretory pathways. Immunocytochem-
ical detection of a1AT in cells treated with SV(AT)
demonstrated predominant juxtanuclear localization of the
serpin, consistent with its presence mainly in the Golgi
complex. Double-staining confocal microscopic analysis
showed that a1AT distribution largely overlapped that ofgiantin, a trans-Golgi marker, and of furin, a trans-Golgi
enzyme.
The localization of a1AT to the TGN in SupT1 and HeLa
cells is the same as in hepatocytes, which are the physio-
logic location of a1AT production. In hepatocytes, a1AT
transits through the TGN and is secreted. We were unable to
detect a1AT in normal lymphocytes [6]: its expression was
detectable only in SV(AT)-transduced cells. Thus, delivery
of a1AT to lymphocytes by SV(AT) allowed transduced
cells to block HIV replication [6].
In HIV-infected lymphocytes, the TGN is the location
of HIV Env proprotein processing. The latter step is
known to be accomplished by cellular serine proteases,
among which furin is the best known. We evaluated
possible a1AT interactions with furin by immunoprecipita-
tion. Transduction of SupT1 cells with SV(AT) resulted in
serpin–serine proteinase interaction and complex forma-
tion. Although controversy persists as to the exact mech-
anism of such inhibition [21,22], the recently reported
crystallographic structure of a serpin–proteinase complex
[21] describes how the conformational change in the a1AT
occurs when the exposed loop of a1AT is cleaved by a
serine protease. After cleavage, the cleaved a1AT ‘‘arm’’
then folds over the protease, pinioning it to the a1AT, and
thus preventing it from attacking other targets. This non-
covalent enzyme–inhibitor complex is very stable; its
dissociation into the active enzyme and the cleaved inhib-
itor is very slow [23].
Once formed, the enzyme–serpin complex may either
form an SDS-stable complex that is rapidly degraded by
proteasomes, or undergo enzymatic cleavage of the serpin
by the enzyme [24]. The partitioning between these two
pathways is a gauge of the efficiency of the serpin: high
levels of serpin deplete target convertases [14]. By immu-
nostaining, continued expression of a1AT for 2 weeks
following SV(AT) transduction greatly reduced levels of
cellular furin Western blot analysis of purified TGN struc-
tures further confirmed SV(AT)-mediated depletion of cel-
lular furin, whereas levels of the control TGN protein,
giantin, were unaffected. Taken together with the likely
central role of furin in processing HIV-1 Env, our findings
strongly suggest that a1AT inhibits gp160 processing by
depleting cellular TGN serine proteases such as furin in
SV(AT)-transduced cells. a1AT thus competes, competitive-
ly inhibits the convertase, and probably accelerates its
degradation.
These data do not establish furin as the principal enzyme
that processes HIV-1 Env, but rather exploit its accessibility
as a prototypical TGN serine protease that is likely to be
involved with process. Indeed, there is considerable evi-
dence that other TGN enzymes participate in processing
HIV Env [25–27]. Whatever enzyme may be involved, it is
important to bear in mind that because the target of a1AT in
inhibiting Env processing is a cellular protein, resistance to
a1AT inhibition of HIV by mutation of the virus is highly
unlikely.
Fig. 8. Structure of HIV p55Gag. Adapted from Jay A. Levy: HIV and the
Pathogenesis of AIDS.
P. Cordelier, D.S. Strayer / Biochimica et Biophysica Acta 1638 (2003) 197–207206The broad and important role of furin in the proteolytic
maturation of proprotein substrates, including the activation
of many pathogen molecules and bacterial toxins has made
this endoprotease a target for the development of potent and
selective inhibitors. Despite their efficiency, these small
molecule inhibitors have had toxic side effects, which have
limited their use as antiviral agents. Native a1AT delivered
by SV(AT) may provide an alternative to the peptides
mimicking the cleavage region of gp160.
The aspartyl protease (PR) encoded by HIV is essential
for processing of viral polyproproteins encoded by the gag
and pol genes into mature viral proteins [28,29]. Mutation
or deletion of the protease gene blocks replication of the
virus [30,31], making the protease an attractive target for
antiviral therapy of AIDS. The development of protease
inhibitor-containing regimens has revolutionized the thera-
py of HIV infection. Highly potent inhibitors of PR have
been developed, and to date, five of these inhibitors have
been approved for clinical use. They bind to the active site
of the PR, and represent transition state analogs. Combi-
nation therapy in which a potent protease inhibitor is
combined with inhibitors of the viral DNA polymerase
reverse transcriptase can result in apparent complete sup-
pression of virus replication. However, the emergence of
drug-resistant HIV-1 variants within a short time is an
important limitation of antiretroviral therapy. The inhibitors
reported thus far are peptides or peptides analogs [32–34],
some of which were originally studied as inhibitors of
other structurally related aspartyl proteases such as pepsin
or renin. Peptides that inhibit HIV-1 protease in vitro with
nanomolar Ki values have been synthesized and shown to
inhibit gag polyprotein processing. However, the pharma-
cokinetic difficulties inherent in the use of peptide-based
inhibitors as pharmaceutical agents, even considering re-
cent advances in delivery and bioavailability, make the
development of macromolecule inhibitors of HIV protease
a high priority.
In a previous study, we demonstrated that a1AT inhibited
activity of HIV-1 PR in SupT1 cells and PBL transduced by
SV(AT) [6]. However, the mechanism(s) of such inhibition
remain to be demonstrated. Here, the possibility of interac-
tion between a1AT and HIV-1 PR was analyzed by several
techniques. HIV challenge of SV(AT)-transduced SupT1
cells caused a redistribution of a1AT: it now localized with
PR, probably in budding virions. This new localization was
in addition to the concentration of a1AT at the TGN, which
was the unique localization of a1AT in cells that were not
challenged with HIV.
The reason for the alteration in a1AT subcellular distri-
bution in HIV-infected cells is unclear. It does not involve
HIV-induced cell death, as SV(AT)-transduced cells survive
HIV infection with both morphologic appearances and
proliferative capacity intact [6].
These findings suggested that a1AT might be incorpo-
rated into developing HIV virions. Western blotting showed
that a1AT was easily detected in virions from SV(AT)-transduced cells. It is likely that this colocalization reflected
interaction with the protease. This possibility is supported
by the finding that a1AT and HIV-1 PR co-immunoprecipi-
tated from HIV virions made by SV(AT)-transduced SupT1
cells. Experiments performed using purified proteins
showed that a1AT bound HIV-1 PR, directly. The strength
of their complex—it largely resisted SDS treatment—is
important in that HIV-1 protease can reactivate following
diffusion of peptidomimetic inhibitors out of virions [32]. It
therefore may be advantageous to use inhibitors of the
protease that would irreversibly bind and thus inactivate
the enzyme.
a1AT binding to PR resulted in inhibition of p55
Gag
cleavage by the protease, in tube. Protein sequencing
revealed that, in the presence of a1AT, p55
Gag processing
was blocked at the stage of a f 40 kDa protein, reflecting
cleavage of p17Gag from p55Gag, leaving the other subfrag-
ments in a f 40 kDa peptide. This result is supported by
the co-immunoprecipitation of a1AT and a f 40 kDa
p55Gag fragment, in HIV virion progeny from cells trans-
duced with SV(AT) (Fig. 8). In addition, this result con-
firmed our previous observation that virions made by a1AT-
producing cells lack detectable p24 [6].
Because homodimerization is required for HIV-1 PR
activity, our findings suggest that an alternative strategy to
small-molecule inhibitors that target the active site of HIV
PR is to devise macromolecules that destabilize or disrupt
dimerization by binding at the dimer surface. Virions
recovered from SV(AT)-transduced cells contained in-
creased monomeric HIV-1 PR and much less of the dimeric
(active) form of HIV-1 PR. The PR dimerization recognition
site is T96LNF. a1AT contains a strongly homologous
sequence, T170VNF, which is present on an exposed a-
helical portion of a1AT. a1AT sequences may thus mimic
the PR dimerization site, and so compete with PR dimer
formation.
a1AT is a suicide inhibitor of serine proteases: reaction
with the protease results in a1AT cleavage. HIV-1 PR can
cleave cellular proteins such as h-actin or vimentin [35]. We
found that a1AT was also cut by HIV-1 PR at amino acid
#25.
a1AT, which is abundant in serum, has been proposed as
a circulating inhibitor of HIV [36]. However, it may be that
the apparently greater effectiveness of intracellular a1AT
delivered by SV(AT), as opposed to extracellular a1AT in
the blood, lies in the protection from a1AT serpin activity
that is afforded by the cell membrane and virion envelope.
Thus, HIV-1 PR and cellular TGN serine proteases may be
shielded from circulating a1AT, and so process HIV Env
proprotein relatively unhindered.
P. Cordelier, D.S. Strayer / Biochimica et Biophysica Acta 1638 (2003) 197–207 207Our data demonstrate that a1AT simultaneously and
differently inhibits processing of HIV-1 Env and Gag. Its
ability to target two HIV proprotein processing at once and
the fact that one of these function involves inhibition of a
cellular enzyme, suggest that HIV resistance to a1AT is
unlikely. Studies currently underway seek to exploit these
findings in devising HIV therapies.Acknowledgements
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